Want to see AVNS full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.16Last Year’s EPS
0.17Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid operational execution and portfolio reshaping that produced revenue outperformance, margin expansion in key segments, strong cash generation, and successful M&A integration (Nexus). However, a material near-term headwind from tariffs (approximately $30M expected in 2026) and lingering softness in certain product lines (surgical pain, GAME READY, HA/IV exits) will weigh on margins in the near term. Management presented a credible mitigation path (China exit, production shift to Mexico/SE Asia, cost containment, pricing) and provided constructive 2026 guidance, indicating confidence in returning to margin improvement in H2 2026 and beyond.Company Guidance
Full-Year Revenue Beat
Net sales for fiscal 2025 were $701 million, exceeding the range revised after Q3 and providing momentum into 2026.
Adjusted Earnings Performance
Delivered $0.94 of adjusted diluted EPS for the full year and $0.29 of adjusted diluted EPS in Q4; full-year adjusted EBITDA was $87 million and Q4 adjusted EBITDA was $28 million.
Strong Specialty Nutrition Systems (SNS) Growth
SNS grew over 8% organically in 2025 (full year). Short-term enteral feeding posted double-digit organic growth globally; long-term feeding grew high single digits; neonatal solutions grew over 6%.
Improved Segment Profitability in Pain Management & Recovery
Pain Management & Recovery operating profit improved to 4% for the full year, a 270-basis-point increase versus prior year, driven by top-line gains and cost management.
Radiofrequency Ablation (RFA) Outperformance
RFA business delivered full-year double-digit organic growth with sustained growth in RFA generator capital sales and expansion of installed base (ESENTEC and TRIDENT product lines noted).
Successful Portfolio Actions and M&A Integration
Completed divestiture of hyaluronic acid business, exited GAME READY rental portion, acquired Nexus Medical (integration described as going very well). Nexus contributed ~ $5 million of revenue and is expected to be a double-digit grower in 2026.
Solid Cash Generation and Strong Balance Sheet
Generated $21 million free cash flow in the quarter and $43 million for the full year. Cash on hand was $90 million with $100 million of debt outstanding and leverage sustainably below 1x.
Tariff Mitigation Progress and Operational Actions
Management executing tariff mitigation steps (cost containment, pricing, temporary exemptions, lobbying) and is confident in plan to exit China syringe manufacturing by June and shift production to Mexico and Southeast Asia.
2026 Guidance Supports Continued Growth
Projected 2026 net sales of $700–$720 million with adjusted diluted EPS guidance of $0.90–$1.10; consolidated organic growth guidance near mid-single-digits (SNS mid- to high-single digits; PM&R low- to mid-single digits).
AVNS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVNS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $24.66 | $24.70 | +0.16% |
Feb 24, 2026 | $15.23 | $13.64 | -10.44% |
Nov 05, 2025 | $11.30 | $10.66 | -5.66% |
Aug 05, 2025 | $11.25 | $9.89 | -12.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avanos Medical (AVNS) report earnings?
Avanos Medical (AVNS) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Avanos Medical (AVNS) earnings time?
Avanos Medical (AVNS) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVNS EPS forecast?
AVNS EPS forecast for the fiscal quarter 2026 (Q2) is 0.16.